Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

Ipilimumab (IPI) blocks CTLA-4 immune checkpoint resulting in T cell activation and enhanced antitumor immunity. IPI improves overall survival (OS) in 22% of patients with metastatic melanoma (MM). We investigated the association of CTLA-4 single nucleotide variants (SNVs) with best overall response...

Descripción completa

Detalles Bibliográficos
Autores principales: Queirolo, Paola, Dozin, Beatrice, Morabito, Anna, Banelli, Barbara, Piccioli, Patrizia, Fava, Cristiana, Leo, Claudio, Carosio, Roberta, Laurent, Stefania, Fontana, Vincenzo, Ferrucci, Pier Francesco, Martinoli, Chiara, Cocorocchio, Emilia, Battaglia, Angelo, Ascierto, Paolo A., Capone, Mariaelena, Simeone, Ester, De Galitiis, Federica, Pagani, Elena, Antonini Cappellini, Gian Carlo, Marchetti, Paolo, Guida, Michele, Tommasi, Stefania, Mandalà, Mario, Merelli, Barbara, Quaglino, Pietro, Fava, Paolo, Guidoboni, Massimo, Romani, Massimo, Spagnolo, Francesco, Pistillo, Maria Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388686/
https://www.ncbi.nlm.nih.gov/pubmed/28446908
http://dx.doi.org/10.3389/fimmu.2017.00386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388686/
https://www.ncbi.nlm.nih.gov/pubmed/28446908
http://dx.doi.org/10.3389/fimmu.2017.00386

Ejemplares similares